From platinum compounds to targeted therapies in advanced thoracic malignancies

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Advances in understanding cancer molecular mechanisms have driven the development of targeted therapies.
• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and crizotinib offer superior efficacy and tolerability for NSCLC with specific mutations.
• Platinum-based chemotherapy remains a standard treatment for advanced small cell lung cancer (SCLC) and thymic malignancies.

Purpose of the Study:

• To review the current landscape of targeted therapies in lung cancer.
• To highlight ongoing research in overcoming resistance to targeted therapies.
• To identify unmet needs in lung cancer treatment, particularly for patients lacking targetable genetic alterations.

Main Methods:

• Review of current literature on targeted therapies and molecular mechanisms in lung cancer.
• Analysis of clinical trial data for EGFR inhibitors, crizotinib, and other emerging targeted agents.
• Discussion of resistance mechanisms and strategies to overcome them.

Main Results:

• EGFR-TKIs and crizotinib are preferred first-line treatments for EGFR-mutant and ALK-translocated NSCLC, respectively.
• Research is actively exploring resistance mechanisms and novel therapeutic targets like ROS, RET, and DDR2.
• A significant proportion of NSCLC patients lack identifiable targetable alterations, necessitating further research into carcinogenesis mechanisms.

Conclusions:

• Targeted therapies have revolutionized NSCLC treatment for patients with specific genetic alterations.
• Overcoming resistance and identifying new targets are critical areas of ongoing research.
• Developing effective therapies for NSCLC without targetable alterations, as well as for SCLC and thymic malignancies, remains a significant challenge.